欢迎来到天天文库
浏览记录
ID:55314776
大小:189.97 KB
页数:3页
时间:2020-05-14
《复方苦参注射液联合拉米夫定治疗慢性乙型肝炎的疗效观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、中西结合研究2015年2月第7卷第l期ResearchofIntegratedTraditionalChineseandWesternMedicine2015FebruaryVo1.7No.j.7.doi:10.3969/j.issn.1674—4616.2015.01.002复方苦参注射液联合拉米夫定治疗慢性乙型肝炎的疗效观察闫雪洁董磊张磊烟台市中医医院,山东烟台264000摘要目的观察复方苦参注射液联合拉米夫定治疗慢性乙型肝炎的临床疗效。方法将140例慢性乙型肝炎患者随机分为治疗组(70例)和对照组(70例),对照组在常规保肝、对症、支持基础治疗上,口服拉
2、米夫定100mg,每日1次。治疗组在对照组治疗基础上,用复方苦参注射液20ml加入250m10.9氯化钠注射液中,静脉滴注,每日1次,2组疗程均为6周,比较2组患者治疗前后肝功能及HBVDNA定量的变化。结果治疗6周后,对照组ALT、GGT水平显著低于治疗前(P3、,治疗组复发率(10.O0)显著低于对照组(17.5O)(P4、dicine,ShandongYantai264000,ChinaAbstractObjectiveToobservetheclinica1effectofcompoundKusheninjectioncombinedwithlamivadineintreatingchronichepatitisB.Methods140patientswithchronichepatitisBweredividedintotreatmentgroup(70cases)andcontrolgroup(70cases)randomly.Thepatientsofcontrolgr5、oupweretreatedbylamivadine,100rag/timeandhimes/dorally.ThepatientsoftreatmentgroupweretreatedbycompoundKusheninjection20ml/timeand1times/dI.v.driponthebasisoftreatmentofthecontrolgroup.Thetherapycourse1astedfor6Weeks.TheindexesofliverfunctionandHBVDNAinbothgroupswerecompared.Results6、Afterthetreatmentfor6weeks.theJevelofALT,GGTinthecontrolgroupandthelevelofALT,AST,TBil,GGTinthetreatmentgroupwereob—viouslylowerthanthosebeforetreatment(P<0.O5).The1evelofALT,AST,TB订,ALP,GGTinthetreatmentgroupwereobviously1owerthanthoseofthecontrolgroup(P7、versionrateofHBVDNAinthetreatmentgroupwasobviouslyhigherthanthatofthecontrolgroup(P8、ativeconversionintr
3、,治疗组复发率(10.O0)显著低于对照组(17.5O)(P4、dicine,ShandongYantai264000,ChinaAbstractObjectiveToobservetheclinica1effectofcompoundKusheninjectioncombinedwithlamivadineintreatingchronichepatitisB.Methods140patientswithchronichepatitisBweredividedintotreatmentgroup(70cases)andcontrolgroup(70cases)randomly.Thepatientsofcontrolgr5、oupweretreatedbylamivadine,100rag/timeandhimes/dorally.ThepatientsoftreatmentgroupweretreatedbycompoundKusheninjection20ml/timeand1times/dI.v.driponthebasisoftreatmentofthecontrolgroup.Thetherapycourse1astedfor6Weeks.TheindexesofliverfunctionandHBVDNAinbothgroupswerecompared.Results6、Afterthetreatmentfor6weeks.theJevelofALT,GGTinthecontrolgroupandthelevelofALT,AST,TBil,GGTinthetreatmentgroupwereob—viouslylowerthanthosebeforetreatment(P<0.O5).The1evelofALT,AST,TB订,ALP,GGTinthetreatmentgroupwereobviously1owerthanthoseofthecontrolgroup(P7、versionrateofHBVDNAinthetreatmentgroupwasobviouslyhigherthanthatofthecontrolgroup(P8、ativeconversionintr
4、dicine,ShandongYantai264000,ChinaAbstractObjectiveToobservetheclinica1effectofcompoundKusheninjectioncombinedwithlamivadineintreatingchronichepatitisB.Methods140patientswithchronichepatitisBweredividedintotreatmentgroup(70cases)andcontrolgroup(70cases)randomly.Thepatientsofcontrolgr
5、oupweretreatedbylamivadine,100rag/timeandhimes/dorally.ThepatientsoftreatmentgroupweretreatedbycompoundKusheninjection20ml/timeand1times/dI.v.driponthebasisoftreatmentofthecontrolgroup.Thetherapycourse1astedfor6Weeks.TheindexesofliverfunctionandHBVDNAinbothgroupswerecompared.Results
6、Afterthetreatmentfor6weeks.theJevelofALT,GGTinthecontrolgroupandthelevelofALT,AST,TBil,GGTinthetreatmentgroupwereob—viouslylowerthanthosebeforetreatment(P<0.O5).The1evelofALT,AST,TB订,ALP,GGTinthetreatmentgroupwereobviously1owerthanthoseofthecontrolgroup(P7、versionrateofHBVDNAinthetreatmentgroupwasobviouslyhigherthanthatofthecontrolgroup(P8、ativeconversionintr
7、versionrateofHBVDNAinthetreatmentgroupwasobviouslyhigherthanthatofthecontrolgroup(P8、ativeconversionintr
8、ativeconversionintr
此文档下载收益归作者所有